Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J S STEWART

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
The Biochemical Journal|May 27, 2018
DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancersSophie R Robinson, Sandra C Viegas, Rute G Matos, et al.
The Quarterly Journal of Medicine|July 1, 1978
A three-year survey of viral hepatitis in West LondonJ S Stewart, L J Farrow, R E Clifford, et al.
British Journal of Cancer|September 16, 2010
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)C M L van Herpen, M E Mauer, R Mesia, et al.
Nature Communications|January 12, 2021
BRD4-mediated repression of p53 is a target for combination therapy in AMLAnne-Louise Latif, Ashley Newcombe, Sha Li, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
The Biochemical Journal|May 27, 2018
DIS3 isoforms vary in their endoribonuclease activity and are differentially expressed within haematological cancersSophie R Robinson, Sandra C Viegas, Rute G Matos, et al.
The Quarterly Journal of Medicine|July 1, 1978
A three-year survey of viral hepatitis in West LondonJ S Stewart, L J Farrow, R E Clifford, et al.
British Journal of Cancer|September 16, 2010
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)C M L van Herpen, M E Mauer, R Mesia, et al.
Nature Communications|January 12, 2021
BRD4-mediated repression of p53 is a target for combination therapy in AMLAnne-Louise Latif, Ashley Newcombe, Sha Li, et al.
Pageof 7